Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections. Review uri icon

Overview

abstract

  • Lysins are bacteriophage-derived enzymes that degrade essential components of bacteria. Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including Staphylococcus aureus, has a low resistance profile, eradicates biofilms, and acts synergistically with other antibiotics. Combinations including exebacase and standard of care antibiotics represent an alternative to antibiotic monotherapies currently used to treat invasive staphylococcal infections. This manuscript reviews what is known about exebacase and explores how this novel agent may be used in the future to treat human bacterial pathogens.

publication date

  • February 17, 2022

Research

keywords

  • Methicillin-Resistant Staphylococcus aureus
  • Staphylococcal Infections

Identity

PubMed Central ID

  • PMC9167414

Scopus Document Identifier

  • 85124719172

Digital Object Identifier (DOI)

  • 10.1016/S1473-3099(04)00976-4

PubMed ID

  • 35175568

Additional Document Info

volume

  • 22

issue

  • 2